Cereblon contributes to cardiac dysfunction by degrading Cav1.2α
Nammi Park1, Jubert Marquez1, Trong Kha Pham1
1Basic Research Laboratory, Department of Physiology, College of Medicine, Smart Marine Therapeutic Center, Cardiovascular and Metabolic Disease Center, Inje University, Busan 614-735, Republic of Korea.
Insights
Cereblon (CRBN) degrades Cav1.2α, worsening heart failure. Reducing CRBN levels or using CRBN degraders enhances cardiac function and may treat heart failure with reduced ejection fraction (HFrEF).
Area of Science:
- Cardiovascular Biology
- Molecular Cardiology
- E3 Ubiquitin Ligase Biology
Background:
- Cereblon (CRBN) targets proteins for degradation via the E3 ubiquitin ligase complex.
- L-type voltage-dependent Ca2+ channel (LTCC) dysfunction is key in heart failure with reduced ejection fraction (HFrEF).
- The role of CRBN in regulating LTCC Cav1.2α during cardiac dysfunction is not well understood.
Purpose of the Study:
- To investigate the role of CRBN in HFrEF.
- To explore CRBN's direct regulatory role in Cav1.2α activity.
- To assess CRBN as a therapeutic target for myocardial dysfunction.
Main Methods:
- Analysis of cardiac tissues from HFrEF patients and controls.
- In vivo and ex vivo studies using CRBN knockout mouse models.
- Investigation of CRBN-Cav1.2α interaction using genetic and pharmacological approaches, including a PROTAC degrader (TD-165).
Main Results:
- Increased CRBN levels were observed in HFrEF cardiac tissues.
- CRBN knockout mice showed enhanced cardiac contractility and LTCC current (ICaL).
- CRBN directly interacts with Cav1.2α, promoting its ubiquitination and degradation, thereby reducing ICaL. Depletion of CRBN increased ICaL and protected against cardiomyopathy.
Conclusions:
- Cereblon selectively degrades Cav1.2α, contributing to cardiac dysfunction in HFrEF.
- Reducing CRBN levels or targeting CRBN degradation presents a promising therapeutic strategy for HFrEF.
Aims:
Cereblon (CRBN) is a substrate receptor of the E3 ubiquitin ligase complex that was reported to target ion channel proteins. L-type voltage-dependent Ca2+ channel (LTCC) density and dysfunction is a critical player in heart failure with reduced ejection fraction (HFrEF). However, the underlying cellular mechanisms by which CRBN regulates LTCC subtype Cav1.2α during cardiac dysfunction remain unclear. Here, we explored the role of CRBN in HFrEF by investigating the direct regulatory role of CRBN in Cav1.2α activity and examining how it can serve as a target to address myocardial dysfunction.
Methods And Results:
Cardiac tissues from HFrEF patients exhibited increased levels of CRBN compared with controls. In vivo and ex vivo studies demonstrated that whole-body CRBN knockout (CRBN-/-) and cardiac-specific knockout mice (Crbnfl/fl/Myh6Cre+) exhibited enhanced cardiac contractility with increased LTCC current (ICaL) compared with their respective controls, which was modulated by the direct interaction of CRBN with Cav1.2α. Mechanistically, the Lon domain of CRBN directly interacted with the N-terminal of Cav1.2α. Increasing CRBN levels enhanced the ubiquitination and proteasomal degradation of Cav1.2α and decreased ICaL. In contrast, genetic or pharmacological depletion of CRBN via TD-165, a novel PROTAC-based CRBN degrader, increased surface expression of Cav1.2α and enhanced ICaL. Low CRBN levels protected the heart against cardiomyopathy in vivo.
Conclusion:
Cereblon selectively degrades Cav1.2α, which in turn facilitates cardiac dysfunction. A targeted approach or an efficient method of reducing CRBN levels could serve as a promising strategy for HFrEF therapeutics.
Related Concept Videos
Mechanism of Cardiac Arrhythmias
G-Protein Gated Ion Channels
Sensory...
Caspases
Pathophysiology of Heart Failure
Cardiac Action Potential
The cardiac action potential process involves a series of phases characterized by the movement of ions across the cardiac cell membranes, leading to the depolarization and repolarization of the cardiac myocytes.
Ionic Basis of Cardiac Action Potentials
Cardiomyopathy IV: Restrictive Cardiomyopathy


